To view this page ensure that Adobe Flash Player version 11.1.0 or greater is installed.

Review Lung Disease Current Perspectives in the Diagnosis and Treatment of Nontuberculous Mycobacterial Pulmonary Disease Michael R Loebinger 1 and Tobias Welte 2 Consultant Respiratory Medicine, Royal Brompton Hospital, London, UK; 2. Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany N ontuberculous mycobacteria (NTM), an extremely diverse group with a wide spectrum of virulence, appear to be rising in prevalence. This may be due to both increased awareness and improved diagnosis, among other factors. Most NTM-pulmonary disease (NTM-PD) infections are caused by the slow growing Mycobacterium avium complex (MAC) however, other species can also cause pulmonary disease including M. abscessus, M. xenopi, M. malmoense and M. kansasii. Symptoms of NTM-PD vary considerably and may include chronic cough, with or without sputum production or haemoptysis. Treatment options are limited at present and associated with significant intolerance, treatment failures and drug–drug interactions. Further prospective studies are needed to define suitable drug regimens for different NTM species and to improve knowledge of the natural history and epidemiology of NTM-PD. Keywords Nontuberculous mycobacteria (NTM), Mycobacterium avium complex (MAC), Mycobacterium avium, Mycobacterium intracellulare, epidemiology, diagnosis, treatment Disclosure: Michael R Loebinger has received consultancy fees from Insmed, but this has not impacted on the article. Tobias Welte has received consultancy fees from Insmed, but this has not impacted on the article. Acknowledgement: Medical writing assistance was provided by Catherine Amey at Touch Medical Media, London and funded by Insmed. Open Access: This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation and reproduction provided the original author(s) and source are given appropriate credit. Received: 9 June 2016 Accepted: 25 July 2016 Citation: European Respiratory & Pulmonary Diseases, 2016;2(2):54–7 Corresponding Author: Michael R Loebinger, Respiratory Medicine, Royal Brompton Hospital, Sydney Street, London, SW3 6NP, UK. E: M.Loebinger@rbht.nhs.uk Support: The publication of this article was supported by Insmed. The views and opinions expressed are those of the authors and not necessarily those of Insmed. Nontuberculous mycobacteria (NTM) are a diverse group of bacteria with a wide spectrum of virulence. 1 They are a microaerobic, non-motile organisms that have a lipid-rich, hydrophobic cell wall that is substantially thicker compared with most other bacteria. 2 NTM are associated with biofilm formation, which contributes to disinfectant- and antibiotic-resistance. 3–5 Many of these organisms are also resistant to high temperature and low pH. 6–8 Ubiquitous in the environment, NTM are found with the greatest concentrations in water sources, both natural and treated, and in soil sources. 9 There are currently over 170 species of mycobacteria and more are likely to be discovered in the future owing to improved culturing techniques and molecular technology advances. 10 The majority of NTM-pulmonary disease (NTM-PD) infections are caused by the slow growing Mycobacterium avium complex (MAC) that includes Mycobacterium avium and Mycobacterium intracellulare, although other species including M. abscessus, M. xenopi, M. malmoense and M. kansasii can also cause lung disease. Not all NTM are considered pathogenic, with species such as Mycobacterium gordonae commonly isolated but not usually associated with the development of NTM-PD and a wide variability reported in the clinical relevance of species. 12 Co-infection with different NTM strains or other bacteria has also been reported. 9,13 NTM lung disease is characterised by clinical, microbiological and radiological criteria. 1 High resolution computed tomography (CT) scanning may consist of a variety of disease patterns including nodular/bronchiectatic disease, fibrocavitary disease, solitary pulmonary nodule, disseminated disease, and hypersensitivity-like disease. 1 Acquisition of NTM is believed to be from the environment; however, emerging literature, using sequencing of NTM isolates, suggest that indirect cross infection of M. abscessus is possible in patients with cystic fibrosis. 14 This has led to changes in infection control standards in these patient groups. 15,16 NTM are treated with antimicrobial chemotherapy, however treatment response is often poor, and side effects significant. Deciding which mycobacteria and patients to treat, and when, and the assessment of response to treatment is very difficult. The purpose of this review is to provide a succinct summary of issues surrounding the epidemiology, diagnosis and treatment of NTM-PD. Epidemiology In contrast to tuberculosis, NTM isolation in pulmonary specimens does not necessarily equate with active pulmonary disease, thus the incidence and prevalence of NTM pulmonary infections is difficult to characterise accurately. 9 In addition, unlike tuberculosis, isolating NTM does not constitute a reportable condition in many countries. Population-based data for prevalence are available mainly from the US, Europe, New Zealand and Australia (where NTM isolation is reportable). 17 These estimates are based on a mixture of microbiology laboratory reports, medical 54 TOU C H ME D ICA L ME D IA